Novo Nordisk's Prescription Boom Sets the Stage for a Pipeline Verdict
01.06.2026 - 10:51:21 | boerse-global.de
The Danish pharma giant has been fighting a two-front war: a punishing share price slide and the relentless advance of competitors. Yet beneath the surface, the oral version of Wegovy is quietly reshaping the narrative. Since its US debut on 5 January 2026, the pill has racked up over 2 million prescriptions — 1.3 million of those in the first quarter alone. By the week ending 17 April, weekly scripts had breached 200,000, a launch velocity that dwarfs earlier GLP-1 entries in the American market. That momentum has translated into hard numbers: first-quarter revenue jumped 24% to DKK 96.8 billion, while profit surged 67%. Management promptly lifted its full-year guidance.
But the stock remains deeply scarred. At roughly DKK 293 (€39.33 or $45.57), it still sits 44% below its 52-week high. Over the past 30 days, however, a 13% recovery suggests investors are sniffing a bargain. The price-to-earnings ratio of about 11 looks historically cheap, and the dividend yield has swelled to 3.84%. Analysts characterise the period as a "transition year", with pricing pressure in the US and doubts about the pipeline's competitive edge capping any exuberance.
The next major test begins on 5 June in New Orleans, where Novo Nordisk will present 40 abstracts at the American Diabetes Association's Scientific Sessions. The spotlight falls squarely on CagriSema, a fixed-dose combination of semaglutide and the long-acting amylin analogue cagrilintide. Phase 3 data from the REIMAGINE-1, -2 and -3 studies in type-2 diabetes will be unveiled, along with phase 2 results for Zenagamtide, an experimental once-weekly GLP-1/amylin injectable that forms part of the company's strategy to branch beyond the semaglutide franchise. Updated cardiometabolic profiles for Ozempic and Wegovy are also on the slate.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The market's reaction will hinge on whether CagriSema can convincingly outperform existing monotherapies on both glycaemic control and weight reduction. Analysts at William Blair and other houses have flagged that a strong showing could restore faith in Novo's pipeline depth. On 7 June, a dedicated R&D investor event will allow management to detail the clinical findings and outline the regulatory path for CagriSema, with an FDA decision expected in the fourth quarter of 2026.
Meanwhile, the competitive landscape is tightening. Eli Lilly's oral drug Foundayo secured inclusion in major US formularies on 1 June, just days before the ADA conference. Novo Nordisk counters with a gross margin of more than 80%, a buffer that helps absorb pricing hits, but the threat is real. The Wegovy pill's rapid uptake provides a solid revenue floor, yet investors are watching to see if the next-generation pipeline can sustain the growth story beyond semaglutide.
The combination of a blockbuster oral launch and a crucial pipeline readout creates an unusual tension. The stock has already shown signs of life after a brutal 38% decline over the past twelve months. The next four days in New Orleans will determine whether that recovery has legs — or whether the transition year drags on.
Ad
Novo Nordisk Stock: New Analysis - 1 June
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
